他汀类药物对银屑病患者疾病严重程度和生活质量的影响：一项系统评价和荟萃分析。

The Impact of Statins on Disease Severity and Quality of Life in Patients with Psoriasis: A Systematic Review and Meta-Analysis.

作者信息

Aleid Abdulsalam Mohammed, Almutairi Ghadah, Alrizqi Rudhab, Nukaly Houriah Yasir, Alkhanani Jomanah Jamal, AlHuraish Deemah Salem, Alshanti Hawazin Yasser, Algaidi Yaser Sami, Alyami Hanan, Alrasheeday Awatif, Alshammari Bushra, Alsaleh Kawthar, Al Mutair Abbas

机构信息

Department of Surgery, Medical College, King Faisal University, Hofuf 31982, Saudi Arabia.

Qassim College of Medicine, Qassim University, Buraydah 51452, Saudi Arabia.

出版信息

Healthcare (Basel). 2024 Jul 31;12(15):1526. doi: 10.3390/healthcare12151526.

DOI:10.3390/healthcare12151526

PMID:39120229

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11311713/

Abstract

BACKGROUND

Psoriasis, a chronic autoimmune condition, imposes significant burdens on patients' well-being. While corticosteroid medications are commonly used, their prolonged use presents risks. Statins, known for their immunoregulatory and anti-inflammatory properties, have emerged as potential alternatives. Previous reviews indicated that statins might improve psoriasis symptoms but showed inconsistent results and lacked meta-analyses that generated pooled effect estimates. Therefore, this study addresses this gap by providing a comprehensive overview of the impact of statins on psoriasis severity and quality of life (QoL) for patients with psoriasis.

METHODS

A thorough search of four electronic databases (PubMed, Cochrane Central Register of Controlled Trials, Scopus, and Science Direct) was conducted for relevant studies published before April 2024.

RESULTS

Seven studies involving 369 patients were included. This meta-analysis showed a statistically significant reduction in PASI scores at week 8 with statin treatment (MD = -1.96, 95% CI [-3.14, -0.77], = 0.001). However, no statistically significant difference was found between statins and placebo at week 12 (MD = 0.19, 95% CI [-0.18, 0.55]). Additionally, DLQI scores indicated a significant improvement in quality of life with statins compared to placebo (MD = -3.16, 95% CI [-5.55, -0.77]).

CONCLUSIONS

Statins can improve disease severity and quality of life in psoriasis patients, suggesting the potential benefits of statin therapy. However, further research is needed to determine the optimal treatment duration, address outcome heterogeneity, and explore additional benefits such as cholesterol and triglyceride reduction.

摘要

背景

银屑病是一种慢性自身免疫性疾病，给患者的健康带来了重大负担。虽然皮质类固醇药物常用，但长期使用存在风险。他汀类药物以其免疫调节和抗炎特性而闻名，已成为潜在的替代药物。先前的综述表明，他汀类药物可能改善银屑病症状，但结果不一致，且缺乏产生合并效应估计值的荟萃分析。因此，本研究通过全面概述他汀类药物对银屑病患者病情严重程度和生活质量的影响来填补这一空白。

方法

对四个电子数据库（PubMed、Cochrane对照试验中央注册库、Scopus和Science Direct）进行了全面检索，以查找2024年4月之前发表的相关研究。

结果

纳入了7项涉及369例患者的研究。该荟萃分析显示，他汀类药物治疗在第8周时PASI评分有统计学意义的降低（MD = -1.96，95%CI [-3.14，-0.77]， = 0.001）。然而，在第12周时，他汀类药物与安慰剂之间未发现统计学显著差异（MD = 0.19，95%CI [-0.18，0.55]）。此外，与安慰剂相比，DLQI评分表明他汀类药物可显著改善生活质量（MD = -3.16，95%CI [-5.55，-0.77]）。